16th International EBHC Symposium

What has health care learnt from the COVID-19 pandemic?
4-5 października 2021 | ONLINE

16. Międzynarodowe Sympozjum Evidence-Based Health Care pt. “What has health care learnt from the COVID-19 pandemic?” ze względu na pandemię COVID-19 odbyło się online w dniach 4-5 października 2021. Mamy nadzieję, że to już ostatnia edycja naszego Sympozjum, która odbywa się w reżimie epidemicznym. Nagrania wystąpień są dostępne na naszym portalu streamingowym: live.ceestahc.org

The programme of the 16th EBHC Symposium was held over the course of 2 days in the following thematic blocks:

  1. Drugs - from market authorization to across reimbursement
  2. Quality = increase the likelihood of desired health outcomes
  3. Health care as one the health determinants
  4. Evidence - RCT … RWE
  5. System transformations - from ... to digital health care
  6. Health policy challenges in the local governments
  7. Successes and challenges in SMA patient care

Organised since 2006, the EBHC Symposium has become a permanent fixture on the conference calendar, also attracting participants from other countries. It is a place for unconstrained discussions on the assessment of health technologies and the effectiveness of systemic solutions. Inevitably, our Symposium has also become a platform for discussing the shape of the Polish healthcare system.

In 2020 and 2021, our entire modern world has experienced a threat which for several generations no longer seemed real. A ubiquitous threat to life, being locked up at home and lack of access to many consumer conveniences and achievements of civilisation have demonstrated how fragile our existence can be. A pandemic wave flooded the world and shattered the existing image of our civilisation.

In Poland, as elsewhere in the world, health care turned out to be the most burdened element, as it yielded to the wave, but did not collapse. In our opinion, this is the sole merit of dedicated employees: doctors, nurses, paramedics and support staff who, despite the threat to health, technical complications, decision chaos and media attacks, continued to do their job the best.

Pandemia jak tsunami bezlitośnie obnażyła wszystkie trwające od lat niedociągnięcia w planowaniu, organizacji czy finansowaniu świadczeń. Po tym potopie wyłoni się nowy krajobraz, w którym solidne elementy systemu opieki zdrowotnej będą nadal trwały. Pojawi się też miejsce na odbudowę tych które nie przetrwały próby. I o tym właśnie dyskutowaliśmy w czasie 16. edycji naszego Sympozjum.

16th International EBHC Symposium What has health care learnt from the COVID-19 pandemic?
October 4-5, 2021 | online

Universal coverage is a hallmark of governments' commitment to improving the well-being of all citizens. Universal coverage is based on the WHO Constitution of 1948, resulting in the recognition of health as a fundamental human right, and the Alma Ata Declaration of 1978, which established the concept of Health For All (HFA). Drug reimbursement is one of the elements of the basic benefit package (BBP), guaranteeing patients access to drug technologies to improve their health. In many European countries (the Netherlands, England, Italy, Belgium) and worldwide, new solutions are being implemented to extend the monitoring of the healthcare system beyond the financial aspects. For modern and flexible healthcare management to be possible, data are needed on the population's health status or the quality of prescribing, as well as monitoring of clinical outcomes for new innovations entering the market. Thanks to widespread computerisation, even basic patient registration results in the collection and accumulation huge amounts of data. This creates the problem of merging data sets, data processing and drawing conclusions. There is certainly still a long way to go before a systemic shift is made from information collected from the country's entire population to the response of the reimbursement system. During this session we will hear about the attempt to set up such a system on the example of the UK drug reimbursement model – from strategic goals to tools for monitoring and evaluating the performance of the system.

In Poland, the Act on Reimbursement, in force since 2012, has introduced a certain order to the drug reimbursement system by adapting it to European standards. The Act has also implemented many modern solutions to improve the availability of drugs, such as tools for rationalisation of systemic decision-making, sets of reimbursement criteria, formalised price negotiations, mandatory HTA and risk-sharing instruments. The new Act on Reimbursement made it possible to provide reimbursement coverage to many modern medicinal products, regardless of indications or availability categories. The Medical Fund introduced in 2020 and the amendment of the Act on Reimbursement are meant to be the answer to delays in reimbursement coverage. In this session we will learn about 10 examples of changes in the Polish healthcare system and the role that the Agency for Health Technology Assessment and Tariff System played in them.

Speakers: Marion Bennie, UK  |  Roman Topór-Mądry, Poland  |  Magdalena Władysiuk, Poland
Sesja 1. Leki - od rejestracji do refundacji. Rys. Maciej Dziadyk maciejdziadyk.pl


Quality in healthcare is a systematic process that enables the design and implementation of effective interventions to improve clinical outcomes by enhancing the range and standard of services. Over many decades, numerous solutions have been developed and experience in improving the quality of healthcare has been accumulated. Despite this wealth of knowledge, a problem often faced by national policy makers in both high and low gross domestic product countries is knowledge of which quality-related strategies would have the most beneficial impact on the outcomes of their healthcare systems. The quality strategy must not only bring about quality improvement, but must also be implementable in the existing healthcare system and have mechanisms in place to monitor the effects of quality improvement. Even where healthcare systems are well developed and equipped, quality remains a major problem and the achieved results are variable and unpredictable. Differentiation in terms of standard occurs at every level: between both healthcare providers within a country and between countries.

People, especially healthcare system managers, play a key role in building and maintaining quality. There is a huge amount of local actions aimed at quality improvement in most countries, but often these activities are carried out in an inadequate political environment and never reach a strategic level. Creators of local solution make decisions based on their competences and the needs of their environment. It is wrong to assume that one solution is adequate for the needs of all patients e.g. sharing a particular condition. For this reason, few local solutions can be scaled-up. Quality building based on the needs of the local healthcare organisation is also easier and carries a lower risk; therefore it is feasible to implement, for example, in developing countries. In these countries, quality improvement is mainly done by increasing healthcare coverage in the population (universal coverage), therefore local quality-improvement strategies with extensive objectives characterised by low complexity can be scaled-up (to a regional or national level).

During this session, the following issues from the Polish healthcare system will be presented: improving patient safety, proposed solutions in pulmonary care and monitoring health effects in breast cancer treatment.

Prelegenci:  |  Małgorzata Czajkowska-Malinowska, Poland  |   Dominik Dziurda, Poland  |  Stanisław Iwańczak, Poland  |  Agnieszka Wojtecka, Poland
Sesja 2: Jakość = zwiększenie szans na pożądane efekty zdrowotne. Rys. Maciej Dziadyk maciejdziadyk.pl

Spinal Muscular Atrophy (SMA) is a genetic neurodegenerative disease affecting motor nerve cells in the spinal cord. It is characterised by progressive wasting of muscles, taking away the patient’s ability to walk, eat or breathe. It affects both newborns and older children or adults. Due to its progressive nature, SMA leads to a significant reduction in the quality of life of patients and their families, being the source of both a psychological and economic overburden. In recent years, significant advances have been made in the research and treatment of SMA.

One of the issues discussed during this session is the national SMA newborn screening programme, given as an example of the medical environment and a social initiative's joint success. Guests of this session will also discuss challenges for the system in SMA patient care based on the “Time is Motor Neuron” report which was developed by a multidisciplinary group of experts.

Speakers: Anna Kostera-Pruszczyk, Poland  |  Katarzyna Kotulska-Jóźwiak, Poland  |  Magdalena Władysiuk, Poland

Social determinants of health (SDoH) social determinants of health, SDoH) to stosunkowo nowy termin w opiece zdrowotnej. Zgodnie z definicją Światowej Organizacji Zdrowia (WHO), SDoH to “warunki, w których ludzie rodzą się, rosną, żyją, pracują i starzeją się. Okoliczności te są kształtowane przez dystrybucję pieniędzy, władzy i zasobów na poziomie globalnym, krajowym i lokalnym”. Zdrowie determinuje również dostęp i jakość opieki medycznej – czasami określane jako medyczne społeczne uwarunkowania zdrowia.

While the pathogens themselves might not discriminate against anyone, social conditions do. The very perception of a given illness depends strongly on whether the general public thinks it results from an unfortunate coincidence or a particular person’s negligence. Every day, COVID-19 morbidity and mortality data reveal how much injustice there has been among the various patient groups; they have been making differences in health outcomes for a long time, and during the pandemic, they could determine if someone lives or dies. The COVID-19 pandemic highlighted that precarious work and exploitative and unfavourable working conditions intersect with a number of factors, including education, socio-economic class and gender, or dependence on third parties (persons with disabilities, people in residential care). The overlapping of these factors increases the risk of contracting a COVID-19 infection in certain groups, as well as the risk of a severe course of the infection. The reduction in access to care for chronically ill patients will have long-term consequences, including those who have managed to avoid contracting COVID-19.

During this session, opinions will be presented on the consequences of the pandemic in the UK, the development of access to genetic testing in Poland, the importance of inequalities, and the evaluation of patient experience in health care.

Speakers: Stephen Campbell, UK  |  Maria Giżewska, Poland  |  Maria Libura, Poland  |  Sophie Staniszewska, UK
Sesja 3: Ochrona zdrowia jako jeden z determinantów zdrowia. Rys. Maciej Dziadyk maciejdziadyk.pl


In recent years, technological developments have helped increase our capacity to collect real-world data (RWD) from the health care system, and the introduction of artificial intelligence (AI) tools helps create real-world evidence (RWE). Scientists, physicians, and public institutions are improving their strategies of integrating RWE into their decision-making processes.

The COVID-19 pandemic imposed the need for a prospective analysis of data flowing from various players in the health care system and accelerated the implementation of solutions. This session will present, among others, Swedish ideas for legal empowerment and an efficient analysis of data from national registers, which were implemented for health care management during the COVID-19 pandemic.

Before the COVID-19 pandemic, RWE data were rarely considered in the decision-making process – especially in analyses performed by HTA agencies. Six of the 13 agencies limited the use of RWE because of a strict hierarchy of evidence, with randomised controlled trials (RCTs) at the top for years. This was the case despite most HTA agencies’ declarations that they accept all evidence on drug efficacy – and therefore, in theory, also RWE in their methodological guidelines.

Systems are now slowly moving towards a change in the approach, and the use of RWE results is becoming more widespread. That way, this new tool will not just be the subject of declarations but actual use. In December 2020, the UK’s NICE published new guidelines on RWE assessment. In turn, the German Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG) has already officially started accepting findings from reliable registers – however with the exclusion of analyses based on electronic health records (EHR). This session will focus on evaluation methodologies using AI, the range of health outcomes evaluated in haematology-oncology, and the potential for innovative drug evaluation solutions.

Speakers:  Mateusz Juchniewicz, Poland  |  Krzysztof Łanda, Poland   |  Elena Petelos, Netherlands/Greece  |  Joanna Rzempała, Poland  | Małgorzata Skweres-Kuchta, Poland  | Björn Wettermark, Sweden
Sesja 4: Dowody naukowe – RCT … RWE. Rys. Maciej Dziadyk maciejdziadyk.pl


Digital transformation in the healthcare system means a positive influence of technology on health care. Telemedicine, Ai-based medical equipment and electronic medical records (including blockchain) are only a few specific examples of the digital transformation observed in health care. They are revolutionising the way we interact with healthcare professionals, how our data is shared to healthcare providers and how the decisions regarding our treatment plans and medical results are being made.

Innovation in this field means not only improving doctors’ work and optimising systems, but more importantly improving patients’ results, safety (e.g. less human errors) and economic efficiency of the systems. During this session, examples of digitalisation solutions in Spain, Croatia and USA, including the examples implemented during the COVID-19 pandemic, will be presented.

Speakers:  Chris L. Pashos, USA  |  Ozren Pezo, Croatia  |  Joan Cornet Prat, Spain


As was the case with past editions of the EBHC Symposium, CEESTAHC continues to collaborate with local governments and to cover local-government-related topics.

The COVID-19 pandemic has caused a dire crisis and we are all experiencing its effects. As a complementary stakeholder responsible for diagnosing the health situation and responding to local needs, the local government has found itself on the front line of this extraordinary situation. And at the beginning of the pandemic, when the situation was rapidly changing, when procedures, law and logistics were not keeping up with the virus, it often stood on this front line alone. In their dramatic calls for assistance, local government officials were insisting on guidelines, procedures and efficiency analyses from the Polish healthcare system decision-makers.

Simultaneously, for a long time (since 2009, following the relevant changes in law), the projects of health policy programmes, as sets of planned interventions (health technologies), have been evaluated by a central institution responsible for health technology assessment. In this case, the pressure to meet the planning and efficacy needs is coming from the top (causing initial discontent of some local governments).

These two seemingly irreconcilable approaches have a common denominator: effective pro-health actions. Nowadays, when healthcare budgets are getting tighter, decisions should be based on substantive, robust foundations, such as epidemiological data, expert guidelines and scientific evidence to an even greater extent. However, local governments' access to available data is a sensitive topic in Poland, because until recently it was hard to find synthetic overviews which would be helpful in retrospective analyses or in planning successful projects. What is problematic are the legal and technical obstacles standing in the way of merging the existing databases and sharing the analyses results in a form that would be useful for entities responsible for planning and implementing actions. Health needs maps and ProfiBaza can change this situation.

During this session we will find out what Heath Technology Assessment (HTA) has to offer public health programmes in Europe. The barriers of implementing HTA into public health programmes will be presented on the example of COVID-19 vaccinations.

When discussing the situation in Poland, we will take a look at the circumstances affecting local governments pursuing health policies when faced with the COVID-19 pandemic and its effects. We will check what has changed over the last two years and how health priorities have shifted.

Local governments are sending a decreasing number of health policy programme drafts to AOTMiT, even though risk group patients are in need of greater support and involvement of all institutions, both central and local. Low vaccination rate, ostracism and reduced social and physical activity of senior citizens, havoc in children’s and teens’ bodies after a year of remote education in front of computer, or the healthcare system's general inefficiency – these are only some of the challenges encountered by local governments.

One of the key challenges which public health needs to confront is providing care to patients who recovered from COVID-19. This is where physiotherapists' work is invaluable. Local governments are physiotherapists’ natural allies for any activities aimed at keeping people fit – both healthy citizens and survivals of various injuries or diseases (including COVID-19). Health policies can be adjusted by actions taken locally. Local governments have been proving it for years with their programmes. That is why the Polish Chamber of Physiotherapists (KIF) collaborates with local governments. Effects of KIF’s work include a physiotherapy programme in the process of comprehensive rehabilitation for COVID-19 convalescents – AOTMiT based its programme for local governments on its basis.

Speakers:  Maciej Krawczyk, Poland  |  Maarten J. Postma, Netherlands  |  Tomasz Jan Prycel, Poland  |  Ewa Urban, Poland  |  Marek Wójcik, Poland

Sesja 6: Wyzwania czekające samorządy w obszarze polityki zdrowotnej. Rys. Maciej Dziadyk maciejdziadyk.pl
16th International EBHC Symposium What has health care learnt from the COVID-19 pandemic?
October 4-5, 2021 | online
Marion Bennie, UK  |  Stephen Campbell, UK  |  Joan Cornet Prat, Spain  |  Małgorzata Czajkowska-Malinowska, Poland  |  Dominik Dziurda, Poland  |  Maria Giżewska, Poland  |  Brian Godman, UK  |  Stanisław Iwańczak, Poland  |  Mateusz Juchniewicz, Poland  |  Grzegorz Juszczyk, Poland  |  Katarzyna Kotulska-Jóźwiak, Poland  |  Maciej Krawczyk, Poland  |  Brygida Kwiatkowska (SPC), Poland  |  Maria Libura, Poland  |  Krzysztof Łanda, Poland  |  Tanja Novakovic, Serbia  |  Chris L. Pashos, USA  |  Elena Petelos, Netherlands/Greece  |  Ozren Pezo, Croatia  |  Robert Plisko, Poland  |  Maarten J. Postma, Netherlands  |  Tomasz Jan Prycel, Poland  |  Joanna Rzempała, Poland  |  Małgorzata Skweres-Kuchta, Poland  |  Sophie Staniszewska, UK  |  Roman Topór-Mądry, Poland  |  Björn Wettermark, Sweden  |  Magdalena Władysiuk, Poland  |  Agnieszka Wojtecka, Poland  |  Marek Wójcik, Poland
Marion Bennie  |  UK

Professor of Pharmacy and Pharmacoepidemiology, University of Strathclyde and Chief Pharmacist, Public Health Scotland. Marion’s joint post is positioned to drive forward an evidence base to better inform the safe and effective use of medicines in routine clinical care. The clinical focus of her research is infection, cardiovascular and cancer including large dataset evaluation to understand evolving patterns of medicines use in routine clinical practice and the development and impact of tailored clinical decision support tools/ health interventions. Marion has lead the provisioning and curation of the Scottish Prescribing Information System (PIS) which captures all individual level community prescribing and dispensing events for the population of Scotland (5.6million) and most recently the national collection and curation of hospital individual level data to support COVID-19 efforts to understand the use and outcome of novel COVID treatments being used in clinical care outwith the clinical trial setting. Current strategic leadership roles include; Associate Director, Health Data Research (HDR) UK Scotland; Immediate past Chair, European Drug Utilisation Research Group (EuroDURG); lead for NHS Scotland Cancer Medicines Outcome Program. Marion is a: Fellow of the Royal Pharmaceutical Society, UK ; a Fellow of the Faculty of Public Health, Royal Colleges of Physicians, UK, and; a fellow of the Royal College of Physicians, Edinburgh. top

Stephen Campbell
Stephen Campbell  |  UK

Professor Stephen Campbell is Chair in Primary Care Research at The University of Manchester and until recently Director of the National Institute for Health, Greater Manchester Patient Safety Translational Research Centre. He is a health services researcher with a particular interest in the quality and patient safety of primary care and across transitional care settings including social care, with a main focus on general/family practice. He has held research appointments as Professor at the University of Melbourne, University of Canberra and the Australian National University in Australia and at the University of Heidelberg in Germany. top

Joan Cornet Prat  |  Spain
Former Director of the ECHAlliance Digital Health Observatory (Dublin), Currently Business Development Advisor at DKV Innolab Digital Health (Barcelona), Senior Expert on the elaboration of Croatian National Digital Health Plan (2020-2025), External Expert of the European Institute of Technology - Health (Munich) and Executive Director of InnoHealth Academy. top
Małgorzata Czajkowska-Malinowska  |  Poland

Head of the Department of Pulmonary Diseases and Respiratory Failure with NIV Unit and Sleep Disorders Unit, Head of the COPD and Respiratory Failure Centre at the Kuyavian and Pomeranian Pulmonology Centre in Bydgoszcz, Doctor of Medical Sciences, specialist in internal diseases and pulmonary diseases, expert in sleep medicine (certified by the Polish Sleep Research Society).

President-Elect of the Polish Respiratory Society, Board Member of the Polish Sleep Research Society, Deputy Head of the Intensive Care and Rehabilitation Chapter of the Polish Respiratory Society, Member of the Non-Invasive Ventilation Group (ERS), Spokesperson for the Polish Respiratory Society since 2012. Co-author of the Polish Respiratory Society Guidelines. Member of the Pulmonary Team appointed by the Ministry of Health (2011). Medical expert in working groups of the Ministry of Health, the Agency for Health Technology Assessment and Tariff System (AOTMiT), the National Health Fund and the WHO. Author of over 100 publications in the field of pneumonology and health promotion, participant in many international multicentre works. Lecturer at pre-graduate and post-graduate training courses for doctors doing their specialisation in pulmonary diseases, balneology and family medicine. Founder and President of the Board of the “ODDECH NADZIEI dla Cierpiących na Schorzenia Płuc i Oskrzeli” foundation focusing on patients with lung and bronchial diseases, between the years 2003 and 2010 Vice-Chair of the Social Council for Persons with Disabilities to the President of Bydgoszcz. Author and coordinator of more than 20 health promotion programmes, particularly in the field of lung disease prevention and anti-smoking activities. Member of the team developing and implementing the "Interactive Programme for the Control of Nicotinism in Patients Treated in Spa Conditions". Organiser of the first COPD and Respiratory Failure Centre in Poland, the first Pulmonary Home Respiratory Treatment Centre in Poland, initiator of Non-Invasive Mechanical Ventilation (NIV) units in Poland, coordinator of the Ministry of Health policy programme entitled "National Programme for Reducing Mortality Due to Chronic Lung Diseases through the Establishment of Non-Invasive Mechanical Ventilation (NIV) Rooms for 2016-2019". She works on improving patient outcomes by developing standards of practice and applying new diagnostic and treatment techniques to lung diseases. top

Dominik Dziurda  |  Poland

Director of the Healthcare Services Department of the Agency for Health Technology Assessment and Tariff System in Poland. Graduate of the Faculty of Pharmacy of the Jagiellonian University Medical College in Cracow (2002) and postgraduate MBA studies for Medical Personnel at the Kozminski University in Warsaw (2010). PhD student at the Warsaw School of Economics. In his professional history, he has been associated with pharmaceutical law, pharmacoeconomics and healthcare system organisation as an: academic lecturer, director for reimbursement in national and central structures within the pharmaceutical sector, as well as an analyst and expert in projects related to access to healthcare and quality management. Head of the technical unit in the Fair and Affordable Pricing project, implemented within the Visegrad Group, a member of the Executive Committee of the POINTer project dedicated to quality indicator systems. At the AOTMiT he is responsible for i.a. projects related to transformation of the guaranteed services system, with focus on therapeutic rehabilitation, coordinated care and clinical management recommendations. top

Maria Giżewska  |  Poland
Prof. Maria Giżewska is a graduate of the Pomeranian Medical Academy. She obtained her specialisation in paediatrics in 1993, metabolic paediatrics in 2014. She received her doctoral degree in 1995 and was habilitated in 2009. She was awarded the title of Professor of Medicine in 2019. Prof. Giżewska is a consultant in metabolic paediatrics for the West Pomeranian Voivodeship, Deputy Head of the Department of Paediatrics, Endocrinology, Diabetology, Metabolic Diseases and Cardiology of the Developmental Age, plenipotentiary of the Rector of the Pomeranian Medical University in Szczecin for international cooperation. Her main scientific interests concern diagnostics and treatment of rare and ultra-rare diseases, including congenital metabolic disorders, especially phenylketonuria, and newborn screening. She is the author and co-author of more than 120 national and international scientific publications with a total IF score of 160 points, Hirsch index 16. Prof. Giżewska implements cross-border Polish-German scientific projects co-financed by the Interreg IVA and VA programmes from the EU funds at the Pomeranian Medical University (PMU) and the Independent Public Clinical Hospital No.1 of the PMU in Szczecin. The cooperation is dedicated to early diagnosis and treatment of newborns with rare diseases, including congenital metabolic disorders, endocrine disorders and recently also congenital immunodeficiency disorders. She is a member of numerous national and international scientific societies (Vice-President of the Scientific Committee of the European Society for Phenylketonuria (ESPKU) and Vice-President of the Polish Society of Phenylketonuria). top
Brian Godman
Brian Godman  |  UK

Brian works with the World Health Organization, governments, health authorities and health insurance companies across continents including Africa, Asia, Europe, Middle East, and South America to enhance prescribing efficiency within scarce resources. This includes potential ways to value and fund new medicines including those for cancer and orphan diseases incorporating suggested models to optimize their use post launch. This has resulted in multiple publications (over 150 listed in Pub Med since 2008) and presentations to address these key issues. top

Stanisław Iwańczak  |  Poland
Stanisław Iwańczak, MSc, Plenipotentiary of the Director for Patient Safety at the Katowice Oncology Centre. Laboratory diagnostician, Graduate of the Pharmaceutical Department of Medical Analytics in Sosnowiec. In the years 1999-2018, Head of the Diagnostics Laboratory at the Katowice Oncology Centre. In the years 1995-1999, employee of the Pharmaceutical Quality Control Laboratory in Katowice. In the years 2010-2014, Deputy Disciplinary Ombudsman of the National Chamber of Laboratory Diagnosticians. Four years ago I became passionate about Patient Safety. I try to share the full scope of this discipline with others. I am constantly looking for people and institutions genuinely interested in implementing patient safety solutions in Poland and around the world. top
Mateusz Juchniewicz  |  Poland

Professor at the Warsaw School of Economics (SGH), Head of the Project Management Department at SGH. Graduate of Management and Marketing at the Warsaw School of Economics. Director and lecturer of Postgraduate Project Management Studies, other postgraduate and MBA studies. Director and participant of research, consulting (e.g. Building an organisation’s project maturity), implementation (e.g. implementation of methodologies, project management offices, business process improvement) and training projects. He cooperates with both the public sector (e.g. the Chancellery of the Prime Minister, the Ministry of Infrastructure, the Supreme Audit Office, other units of the public finance sector) and the private sector (mainly companies from the energy, transport, R&D and construction sectors). He specialises in project management maturity, project risk management and projects in multicultural environments. Author of several dozen publications in the field of management, including the first monograph in Poland devoted to project management maturity of organisations. Certified project manager in project (PRINCE2® and AgilePM®), portfolio (MoP®) and risk (M_o_R®) management. Member of PMI, IPMA and co-founder of the Association of Project Managers – Graduates of Postgraduate Studies in Project Management at the Warsaw School of Economics. top

Anna Kostera-Pruszczyk  |  Poland
Professor Anna Kostera-Pruszczyk, MD, PhD, is a specialist in the field of neurology and child neurology, the Head of the Department of Neurology at the Medical University of Warsaw, which is a part of the European Reference Network on Rare Neuromuscular Diseases (ERN-NMD). She was awarded the title of professor of medicine in 2016. Professor Anna Kostera-Pruszczyk MD, PhD, specialises in the field of neuromuscular diseases. In terms of scientific interests and clinical work, her particular focus is on acquired and hereditary peripheral nervous system diseases, including spinal muscular atrophy (SMA). She acts as Vice-Chair of the Main Board of the Polish Society of Child Neurologists. Moreover, she is a member of the Expert Panel of the European Academy of Neurology for Neuromuscular diseases and a member of the Central Board of the Polish Neurological Society and numerous other scientific societies, both domestic and foreign. She is the author and co-author of publications with a cumulative Impact Factor of over 360. top
Katarzyna Kotulska-Jóźwiak  |  Poland
Professor of neurology and paediatric neurology, Head of the Neurology and Epileptology Clinic at the Children’s Memorial Health Institute, Vice-Chairman of the Scientific Council at the Children’s Memorial Health Institute (CMHI) in Warsaw which is Poland’s reference paediatric hospital. Polish representative to the Board of EU Member States for European Reference Networks, vice-chair of the team on rare diseases, Head of the team coordinating the programme for treatment of spinal muscular atrophy. Member of the MAB BrainCity Scientific Committee. Graduate of the Medical University of Silesia, she conducts research in the field of developmental neurology, especially in the field of epileptogenesis and skin and nerve diseases. In the past, Katarzyna Kotulska-Jóźwiak was head and executor of several national and international grants. Author of over 150 peer-reviewed articles published in scientific journals.  top
Maciej Krawczyk  |  Poland

President of the Polish Council of Physiotherapists. PhD in medical sciences, PhD in Physical Culture in Rehabilitation, physiotherapy specialist. Graduate of the Faculty of Rehabilitation of the Józef Piłsudski University of Physical Education and an academic teacher at the university for 30 years. Employee of the Second Department of Neurology of the Institute of Neurology with the first stroke unit in Poland. Researcher and member of the Scientific Council at the Institute of Psychiatry and Neurology. Co-author of the Act on the physiotherapist profession. He specialises in the physiotherapy of patients who suffered damage to the central nervous system. Maciej Krawczyk has been the President of the National Council of Physiotherapists since 28 December 2016. He coordinates the work of the Polish Council of Physiotherapists which executes the tasks determined by the 1st National Congress of Physiotherapists; he supervises the work of the Polish Chamber of Physiotherapists Office, he represents the Polish Chamber of Physiotherapists before external entities (among others, state institutions).
Professional interests: reconstructive neurology, anthropology, kinesiology.
Hobbies: road cycling, downhill skiing, literature, cooking.  top

Brygida Kwiatkowska
Brygida Kwiatkowska (SPC)  |  Poland
Rheumathologist, Deputy Director for Clinical Affairs at the National Institute of Geriatrics, Rheumatology and Rehabilitation in Warsaw, Chairperson of the National Council of Rheumathology, Secretary of the Warsaw unit of the Polish Rheumatology Association. Dr. Kwiatkowska’s academic interests include the diagnosis and treatment of rheumatic diseases. She conducts multi-directional work thus contributing to other medical disciplines related to rheumatic diseases. She promotes the use of modern diagnostic techniques in diagnosing rheumatic diseases and introduces the latest available therapeutic methods. Her academic achievements comprise 46 publications: 12 original full-text scientific papers, 26 review articles, 4 case reports, 11 textbook chapters, including 2 chapters to an international textbook (published in English), 2 editorial commentaries. She is the first author of the majority of the papers, playing the leading role in the creation of the concept, development of the results and preparation for print. In addition, she has published 15 congress reports in supplements for Polish and foreign scientific journals. top
Maria Libura
Maria Libura  |  Poland

Head of Medical Training and Simulation Centre, University of Warmia and Mazury in Olsztyn, vice-President of The Polish Society for Medical Communication, healthcare expert of the Jagiellonian Club Analytical Centre, President of Polish Prader–Willi Syndrome Association. Member of the Expert Board to the Patients Ombudsman.  top

Krzysztof Łanda
Krzysztof Łanda  |  Poland
President of MedInvest Scanner. Krzysztof was Deputy Minister of Health in 2015-2017 and was responsible for drug policy, reimbursement and prices of medical devices, mapping of health needs, investments in health care, prices of health services and the basic benefits package. Krzysztof was previously the CEO of HTA Audit, a company dealing with the quality assessment of HTA reports addressed to authorities and public institutions and the President of the Watch Health Care Foundation. In 2010-2011 he was President of the Central & Eastern European Society of Technology Assessment in Health Care. In 2006-2007 was a Director of the Drug Policy Department in the Central Office of the National Health Fund. In 2004 Krzysztof was elected to the Board of Directors of Health Technology Assessment International (HTAi) where he remained until mid-2007. In 2010-2012 and in 2006-2008 Krzysztof led capacity building in HTA in Ukraine and in Serbia. He was a team leader of a World Bank project aimed at introducing EBHC principles in Serbia.  top
Tanja Novakovic  |  Serbia
Tanja Novakovic MSc Pharm is director of ZEM Solutions Ltd and the president of the Pharmacoeconomics Section within the Pharmaceutical Association of Serbia. After finished postgraduate studies in Health Economics at Ghent University in Belgium she has made significant contributions to developing knowledge and experience in heath economics and HTA, organizing many international Conferences and bringing together world experts in this field. She is author of the “Handbook for pharmacoeconomic evaluations” (2006), the first publication in the field of pharmacoeconomics in the Serbian language, Serbian pharmacoeconomic guidelines (2011) and co-author of the book Health Economics (2014). Tanja participated in several projects in a wide range of fields, including: Big Data, disease areas such as oncology, rare diseases, nutrition, Rheumatology, biosimilars and has previously been involved in World Bank and Ministry of Health of Serbia projects. Tanja has organized and presented in many national meetings and international conferences which have resulted in international cooperation in education and the developing of pharmacoeconomics and HTA in Serbia. top
Chris L. Pashos  |  USA

Dr. Pashos serves on the Board of Directors, and is Chief Medical Officer and Head of Research Partnerships, of Genesis Research, an international consultancy supporting the life sciences industry.  Genesis Research is known for its unique partnership model through which it provides evidence-based, technology-enabled and scientifically rigorous solutions across all aspects of value demonstration.  Besides his work in consulting, Dr. Pashos's career has spanned periods in academia (Harvard Medical School) and life sciences companies (Takeda and AbbVie). A Charter Member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Dr. Pashos served as ISPOR President in 2008-2009.   top

Elena Petelos  |  Netherlands / Greece
Elena Petelos is a public health specialist, with an educational background in Medicine, Molecular Biology, and Molecular Oncology. She has been a Research Associate of CSFM of the UoC since 2007, and a Senior Research Fellow for Public Health / Lecturer for Evidence-Based Medicine and Evidence-Informed Policy, with teaching and research responsibilities since 2016. She also teaches at the MSc in Public Health programme of Maastricht University, and she represents this university in the newly formed network of International Network for Social Intervention (INSIA), established by the Swedish government (SBU) in 2020. She is an expert for outcomes and molecular diagnostics for the European Commission (COSME-EASME, Innovative Medicine Initiative (IMI) and multiple public health instruments), and for the Medical Research Council (MRC) of the UKRI, the national funding agency of the United Kingdom. She is also a member of the Steering Group of the European Health Information Initiative of the World Health Organization (WHO) since 2017, elected as Vice-Chair of the Sub-group on Evidence-Informed Policy (2018) and elected as Chair of the Subgroup of EU, OECD, WHO - EHII on Mapping indicators across the European region (2019). She serves in the Editorial Board of the European Journal of Midwifery since 2017, and as a Reviewer for multiple journals, incl. the European Journal of Public Health, the International Journal for Technology Assessment in Healthcare, and as Review Editor for Infectious Diseases - Surveillance, Prevention and Treatment (Frontiers in Medicine) and a Review Editor for Public Health Education and Promotion (Frontiers in Public Health). top
Ozren Pezo  |  Croatia

Obecnie zajmowane stanowiska: Niezależny ekspert ds. biznesu i technologii informacyjno-komunikacyjnych (ICT), konsultant Banku Światowego i Komisji Europejskiej, członek Rady Nadzorczej “HL7 organization Croatia”. Ozren Pezo ukończył studia na kierunku Informatyka i uzyskał dyplom z Zarządzania na Uniwersytecie w Zagrzebiu oraz tytuł magistra informatyki na Politechnice w Mediolanie. Pan Pezo pracował jako dyrektor ds. informatyki w Chorwackim Funduszu Ubezpieczeń Zdrowotnych (CHIF) w latach 2014-2017. Zajmowane stanowiska i pełnione obowiązki w tamtych latach: Przewodniczący Rady Zarządzającej Chorwackiego Instytutu Telemedycyny, członek Narodowego Komitetu ds. Strategii IT w Ochronie Zdrowia, krajowy współpracownik w European Cloud in Health Advisory Council. Pan Pezo był odpowiedzialny za planowanie strategiczne, rozwój i doskonałość operacyjną IT w CHIF i chorwackich projektach narodowych e-Zdrowia. (e-recepta, e-skierowanie, e-Booking, e-Schedule Line Findings, portal BI, narzędzie do wykrywania oszustw, portal e-Citizen health, system EHR (elektroniczny rejestr zdrowia), itp.) Wcześniej pracował na różnych stanowiskach kierowniczych w kilku przedsiębiorstwach z branży ICT w regionie Europy Południowo-Wschodniej, w tym przez 9 lat w Microsoft. Przez ostatnie 4 lata pracował jako międzynarodowy ekspert w zakresie ICT i ekspert biznesowy oraz konsultant Banku Światowego, Komisji Europejskiej przy różnych projektach reformy służby zdrowia w Azji, Afryce i Europie. Jego kompetencje dotyczą narodowej strategii e-Zdrowia oraz rozwoju i wdrażania systemów e-Zdrowia, optymalizacji procesów ubezpieczeń zdrowotnych, systemów informacji o ubezpieczeniach zdrowotnych, wykrywania i zapobiegania oszustwom w systemie opieki zdrowotnej. Prelegent, prezenter i panelista na ponad 15 krajowych, regionalnych i międzynarodowych konferencjach z zakresu IT/ zdrowia. top

Robert Plisko  |  Poland

Robert Plisko is CEO at HTA Consulting since 2006 and one of the company’s founders. He obtained his Master of Economics title at the Cracow University of Economics. His professional career started at the National Centre for Quality Assessment in Healthcare. Robert Plisko is the author of numerous publications on HTA and health care. He is head of the Economic Analyses Department at HTA Consulting. top

Maarten J. Postma  |  Netherlands

Maarten J. Postma jest przewodniczącym Global Health Economics w Uniwersyteckim Centrum Medycznym w Groningen (UMCG) oraz wydziału Ekonomii i Biznesu, będących częścią Uniwersytetu w Groningen, oraz kierownikiem instytutu badawczego UMCG o nazwie „SHARE”. Jest również profesorem farmakoekonomiki na Wydziale Farmaceutycznym Uniwersytetu w Groningen oraz dwóch wydziałach w Indonezji – Wydział Farmakologii na Universitas Airlangga w Surabai oraz Wydział Innowacji Opieki Farmaceutycznej na Universitas Padjadjaran w Bandungu. W szczególności przewodniczy on sześćdziesięcioosobowemu zespołowi pracowników, doktorów i doktorów habilitowanych, którzy są badaczami ekonomiki zdrowia oraz farmakoekonomiki i mają wkład w wiele międzynarodowych organizacji badawczych i komunikację naukową. Na obszary badawcze składają się metody opłacalności ekonomicznej, przykładowo w wakcynologii, transfuzjologii, zapobieganiu chorobom przewlekłym (i powikłaniom), lekach sierocych oraz medycynie personalizowanej. Zarówno w przeszłości, jak i obecnie zasiada w różnych komisjach doradzających rządowi holenderskiemu w sprawie refundacji leków i szczepionek (Kolegium Ubezpieczeń Zdrowotnych Holenderskiego Instytutu Zdrowia (CVZ/ZiNL) i Holenderska Rada Zdrowia). Ponadto jest on doradcą różnych firm konsultingowych związanych ze zdrowiem i ekonomią, firm farmaceutycznych na całym świecie oraz Ministerstw Zdrowia w państwach ościennych. Jest on również członkiem wielu redakcji naukowych czasopism, zasiada w komitetach doradczych firm farmaceutycznych, jest specjalistycznym doradcą WHO i członkiem komitetów doradczych WHO (SAGE). Jest członkiem brytyjskiego Komitetu ds. Szczepionek i Szczepień oraz doradcą walijskiego AWMSG (All Wales Medicines Strategy Group). Jego specjalizacją jest rola farmakoekonomiki i ekonomiki zdrowia w procesie refundacji. Maarten J. Postma posiada tytuł magistra ekonometrii oraz doktora ekonomiki zdrowia. top

Tomasz Jan Prycel
Tomasz Jan Prycel  |  Poland
Managing Director of CEESTAHC. Graduate of the Faculty of Medicine of the Medical University in Łódź and Postgraduate  Health Care Management Studies in the Nofer Institute of Occupational Medicine. Expert in ​​cooperation and creation of health projects with local government units, with many years of experience in creating an educational platform for developing high-quality health programmes in important areas of public health. President of the European Foundation for Solving Health Problems (Europejska Fundacja Rozwiązywania Problemów Zdrowotnych). Co-creator of the “Zdrowie/Człowiek/Profilaktyka” educational programme, aimed at local governments and employers. Initiator of www.dobreprogramyzdrowotne.pl, a website containing a Health Programme Creator and educational materials for creators of health policy programmes. top
Joanna Rzempała  |  Poland
PhD in economics, Senior Lecturer in the Department of Organisation and Management at the Faculty of Economics, Finance and Management of the University of Szczecin. Lecturer in the field of project management. She is the director and a lecturer of "Project Manager" postgraduate studies at the University of Szczecin. Vice President of IPMA Poland responsible for student certification and cooperation with universities. Manager of teaching and business projects, independent consultant specialising in project financial management. IPMA-Student Programme Manager, Coordinator of the National Project Master Competition for the best diploma thesis in project management. She holds the title of Certified Senior Project Manager IPMA-B, the Green Project Management Global- b Certificate and the certificate of the Ministry of Finance for providing accounting services as well as the PRINCE2 Foundation project management certificate. She was awarded the title of Project Management 2015 Atlas for spreading the idea and knowledge of project management in Poland. Author of scientific publications, including in the field of management. She has been a member of the Finance Committee of IPMA International since March 2018.  top
Małgorzata Skweres-Kuchta  |  Poland
PhD in economics, professionally involved with the University of Szczecin; her field of work involves management of healthcare systems and support for children with rare diseases; member of the Council of Experts on Rare Diseases at Medyczna Racja Stanu (Medical National Interest, Polish think-tank), CEO of Platynowa Drużyna (Platinum Team Foundation) – patient organisation for patients with type 2 neuronal ceroid lipofuscinosis (CLN2); member of the NCL Gruppe Deutschland e.V. patient organisation. top
Sophie Söderholm Werkö  |  Sweden
Manager International Relations & Patient Engagement, The Swedish Agency for Health Technology Assessment and Assessment of Social Services. Sophie has an MSc in Business Administration and a PhD from the University of Stockholm. She has a longstanding engagement with HTA and started in HTA as Project Director at The Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU). In 2012 she was appointed Manager of International Relations at SBU, responsible for coordinating SBU’s international work and she is also leading the work on Patient Involvement at SBU. As Chair of the International Network of Agencies for Health Technology Assessment (INAHTA) until 2020, she had an important role of leading the global network of publicly funded HTA agencies. She has participated in the work of the European network for Health Technology Assessment (EUnetHTA) since 2009 and represents Sweden in the EU HTA Network (HTAN). Recently she acted as regional advisor to the WHO Egypt office and the WHO in the EMRO Region. She publishes frequently in scientific journals and acts as reviewer and associated editor in several journals. top
Sophie Staniszewska  |  UK
Professor Sophie Staniszewska leads the Patient and Public Involvement and Engagement (PPIE) and Experiences of Care Research Programme at Warwick Medical School, England. She focuses on developing the evidence base of PPIE in areas such as mathematical and economic modelling, genomics and enabling data and gastrointestinal infections. She has recently co-edited a special issue of the International Journal of Technology Assessment in Health Care with Dr Sophie Werko, focusing on patient and public involvement in HTA. Sophie was co-chair of the Methods and Impact sub-group 9with Dr Werko) of the Citizen and Patient Involvement HTAi Interest Group. Sophie is Co-editor in Chief of a Springer Nature Journal, Research Involvement and EngagementSophie is a founding member of the International PPI Network which aims to create global understanding and synergy in patient and public involvement in health and social care research. top
Roman Topór-Mądry
Roman Topór-Mądry  |  Poland
Roman Topór-Mądry, MD – President of the Agency for Health Technology Assessment and Tariff System. Doctor, specialist in public health, epidemiologist. Regional consultant in public health for the Małopolskie voivodeship. Deputy Director of the Institute of Public Health of the Faculty of Health Sciences at the Jagiellonian University Medical College. Participant and coordinator of many research projects, he worked in advisory teams to, i.a. the Ministry of Health, scientific societies, local governments, the European Commission, the World Bank. top
Ewa Urban
Ewa Urban  |  Poland
Ewa Urban, MD, has worked in the National Institute of Public Health PZH – National Research Institute, in the Department of Health Promotion and Chronic Disease Prevention as Senior Technology Research Specialist, and she has been acting Head of that Department since 2018. Moreover, she is a lecturer at the Postgraduate Medical Education Centre and at the College of Rehabilitation in Warsaw. Ewa Urban is the co-author of scholarly articles in the field of public health and health promotion. She took part in numerous projects, incl. ProfiBaza — digital sharing of public information about the people’s health-related situation and implementation of health programmes addressing disease prevention and health promotion in Poland; Priority on NCD: Increased access to interventions to prevent and manage noncommunicable diseases and their risk factors; Development of an innovative set of indices in the public health area, tailored for the Polish healthcare system; Local partnerships benefiting residents; Assessment of necessary public health actions taken in Poland (EPHOs). top
Björn Wettermark  |  Sweden
Björn Wettermark, M.Sc.Pharm, PhD is professor of pharmacoepidemiology at Uppsala university, Sweden and visiting professor at Vilnius university, Lithuania. His research focus mainly on drug utilization as a tool in health policy including prescribing quality indicators, international comparisons of drug utilization, evaluation of prescribing doctors´ adherence to guidelines and patient adherence to treatment as well as intervention studies to promote rational use of drugs. He has previously had various managerial positions in the health region of Stockholm as well as other commitments including membership in national and regional strategic groups on medicine management, scientific advisor to the Swedish Medical Products Agency as well as past chair of the European Drug Utilization Research group, the European chapter of the International Society for Pharmacoepidemiology. top
Magdalena Władysiuk
Magdalena Władysiuk  |  Poland
President of CEESTAHC Society, CEO of MedInvest Scanner, Vice President of HTA Consulting.In HTA Consulting, she is responsible for the strategic development of the company through research and services development, new product launch and marketing. Ms. Wladysiuk main and primary aim is to provide high quality information or data based on evidence based medicine or health technology assessment methodology not only in Poland but in Europe and Asia. Key role of her work is to improve patient outcomes through better healthcare decisions. In CEESTAHC she was responsible for the establishing and providing wide connection platform for discussion for all stakeholders in health care system. CEESTAHC mission is to improve the quality of health care systems value with the use of evidence. She graduatd Medical Academy in Lublin and MBA, economy in Kozminski Academy in Warsaw. She was Member of HTAi Annual Meeting in 2006-2008. top
Agnieszka Wojtecka  |  Poland
Author of publications on issues related to senior care, active ageing and access to health e-information. Co-author of reports on monitoring public health tasks. Member of research teams and co-author of mid-term ROP 2014-2020 evaluation studies for mid-term review in selected voivodeships. Coordinator of the "Third Age in Health" health promotion programme implemented by the Gdańsk Centre for Health Promotion and Addiction Prevention. Coordinator in a project co-financed by the EU concerning an internship programme for Environmental Health and Public Health students. Psychotherapist. Member of the Polish Society for Health Programs and the Association of Christian Psychologists. top
Marek Wójcik
Marek Wójcik  |  Poland

Marek Wójcik, healthcare expert at the Association of Polish Cities, Deputy Minister of Administration and Digitisation in the years 2014-2015, long-term participant of legislative works in the Polish Sejm and Senate; member of the health and social policy team of the Joint Commission of the Government and Local Governments and participant in the work of the Council for Social Dialogue. Since 2004, he has served three terms as chairman of the Council of the Małopolskie Regional Branch of the National Health Fund, an expert to the Minister of Health for restructuring healthcare facilities and ownership transformations (2009-2011), member of the Council for Public Health and of the Scientific Council of the National Influenza Control Programme. He supervises the activities of medical entities subordinate to the Sądecka Municipal Public Services Zone (pilot project), and the Nowy Sącz poviat. Author of publications on public health and health programmes created by local governments. In his didactic activity, he collaborates i.a. with the Cracow University of Economics, Lazarski University in Warsaw, Warsaw School of Economics, Medical University of Łódź, WSB – National Louis University in Nowy Sącz, and University of Business and Entrepreneurship in Ostrowiec Świętokrzyski. top


bio top

16th International EBHC Symposium What has health care learnt from the COVID-19 pandemic?
October 4-5, 2021 | online

Previous editions

EBHC 2006 archiwum

Zobacz edycję 2006

EBHC 2007 archiwum

Zobacz edycję 2007

EBHC 2008 archiwum

Zobacz edycję 2008

EBHC 2009 archiwum

Zobacz edycję 2009

Zobacz edycję 2010

Zobacz edycję 2011

Zobacz edycję 2012

Zobacz edycję 2013

Zobacz edycję 2014

Zobacz edycję 2015

Zobacz edycję 2016

Zobacz edycję 2017

Zobacz edycję 2018

Zobacz edycję 2019

Zobacz edycję 2020

Zobacz edycję 2021

Zobacz edycję 2022

en_GBEnglish (UK)